Needham & Company Downgrades Hyperion Therapeutics (HPTX) to Hold Amid Takeover Deal
Tweet
Share
E-mailGet Alerts HPTX Hot Sheet
Price: $45.99 --0%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company downgraded Hyperion Therapeutics (NASDAQ: HPTX) from Buy to Hold amid the Horizon acquisition announcement.
For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.
Shares of Hyperion Therapeutics closed at $45.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Needham Reiterates Buy Rating on Cerebras Systems (CBRS)
- Celcuity Inc (CELC) PT Lowered to $140 at Needham
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & Company, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
